BioinvestGPT User Guide — Clinically Derisk M&A (REMEDIATION)

Independently validate a pipeline asset valuation with BVCT-predicted effect sizes before you sign a term sheet.

When to use this mission

The REMEDIATION mission — surfaced from the Hub as Clinically Derisk M&A — is for due diligence on an acquisition target. Use it to independently validate a pipeline asset valuation before you sign a term sheet, instead of relying on analyst consensus or the target company's own projections.

What this answers: "Is the asking price justified by the asset's likely clinical effect size?" The platform generates independent BVCT-predicted effect sizes for each pipeline asset and ends in a single GO / NO-GO readout you can take into the deal room.

Typical situations

Evaluating a biotech acquisition where the headline valuation rests on one or two lead assets.
Pressure-testing a banker's or target's projected effect size against an independent causal simulation.
Pricing a known risk — a crowded competitive field, a thin mechanism, an unproven indication — into the offer.

Tip: Run REMEDIATION once per lead asset rather than once per company. A portfolio valuation is only as defensible as the per-asset effect sizes underneath it.

For the variant of this workflow that pulls a real ongoing trial by sponsor or ticker and reads it out against ClinicalTrials.gov, see the Free Trial chapter.

Enter the deal parameters

From the Hub, click "Start" on the Clinically Derisk M&A card. The Validator opens on the REMEDIATION mission. Fill in the deal parameters that frame the diligence question:

Field	What to enter
Target Company	The acquisition target you are evaluating.
Therapeutic Area	The asset's clinical domain — Oncology, Immunology, etc.
Acquisition Thesis	Why this asset is valuable — the strategic rationale you are testing.
Asking Price	The proposed valuation on the table.
Key Risk Factors	The known concerns — competition, mechanism uncertainty, unproven indication, regulatory exposure.

Be specific in the Acquisition Thesis and Key Risk Factors. The independent valuation in the next section reasons from what you frame here — a vague thesis produces a vague readout.

Tip: State the Asking Price in the same currency and basis you will use in the term sheet, so the GO/NO-GO readout maps directly onto the number under negotiation.

The independent effect-size valuation

Once the deal parameters are submitted, the platform generates independent BVCT-predicted effect sizes for each pipeline asset — not analyst consensus, not the target company's projections. The simulation reasons from disease biology and the asset mechanism to a defensible effect size, then weighs that against the Asking Price you entered.

Why "independent" is the point: In a deal room, the seller's numbers are the ones being challenged. REMEDIATION gives you a third number — derived from causal simulation rather than from either side's spreadsheet — so the negotiation has an objective anchor.

Reading the result

The mission resolves to the same readout as every other BVCT run:

Readout	What it means for the deal
GO	The predicted effect size supports the Asking Price — the thesis holds under independent simulation.
NO-GO	The predicted effect size does not justify the valuation — revisit the price, the thesis, or the risk factors before proceeding.

Do not over-read a single asset. A NO-GO on one lead asset does not condemn the whole company; a GO does not clear it. Run each lead asset and assemble the per-asset readouts into your overall valuation view.

BVCT-predicted effect sizes are tracked prospectively against real-world clinical outcomes. You can review the public track record at data.bioinvestgpt.com.

Next: To validate against a real, in-flight study — pulling the target's ongoing trials by sponsor or ticker and reading them out — use the Free Trial variant of this workflow.

BioinvestGPT BVCT Platform User Guide — Clinically Derisk M&A (REMEDIATION). BVCT outputs are model-based decision-support analyses, not investment advice. Prospective track record: data.bioinvestgpt.com.